{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:36:56Z","timestamp":1762015016761,"version":"build-2065373602"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sleep Breath"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11325-019-01920-5","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T10:02:30Z","timestamp":1565776950000},"page":"923-929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The serum YKL-40 level is a potential biomarker for OSAHS: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"24","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinhua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"issue":"3","key":"1920_CR1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7326\/0003-4819-142-3-200502010-00010","volume":"142","author":"SM Caples","year":"2005","unstructured":"Caples SM, Gami AS, Somers VK (2005) Obstructive sleep apnea. Ann Intern Med 142(3):187\u2013197","journal-title":"Ann Intern Med"},{"issue":"2","key":"1920_CR2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1513\/pats.200709-155MG","volume":"5","author":"NM Punjabi","year":"2008","unstructured":"Punjabi NM (2008) The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 5(2):136\u2013143","journal-title":"Proc Am Thorac Soc"},{"issue":"5","key":"1920_CR3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1536\/ihj.46.801","volume":"46","author":"O Kokturk","year":"2005","unstructured":"Kokturk O, Ciftci TU, Mollarecep E, Ciftci B (2005) Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J 46(5):801\u2013809","journal-title":"Int Heart J"},{"issue":"4","key":"1920_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11325-009-0259-1","volume":"13","author":"N Al Lawati","year":"2009","unstructured":"Al Lawati N, Mulgrew A, Cheema R, vanEeden S, Butt A, Fleetham J, Ryan F, Ayas N (2009) Pro-atherogenic cytokine profile of patients with suspected obstructive sleep apnea. Sleep Breath 13(4):391\u2013395","journal-title":"Sleep Breath"},{"issue":"1","key":"1920_CR5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11325-005-0046-6","volume":"10","author":"AK Htoo","year":"2006","unstructured":"Htoo AK, Greenberg H, Tongia S, Chen G, Henderson T, Wilson D, Liu SF (2006) Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 10(1):43\u201350","journal-title":"Sleep Breath"},{"issue":"4","key":"1920_CR6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11325-006-0074-x","volume":"10","author":"M Yamauchi","year":"2006","unstructured":"Yamauchi M, Tamaki S, Tomoda K, Yoshikawa M, Fukuoka A, Makinodan K, Koyama N, Suzuki T, Kimura H (2006) Evidence for activation of nuclear factor kappaB in obstructive sleep apnea. Sleep Breath 10(4):189\u2013193","journal-title":"Sleep Breath"},{"issue":"10","key":"1920_CR7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.5664\/jcsm.3070","volume":"9","author":"R Nadeem","year":"2013","unstructured":"Nadeem R, Molnar J, Madbouly EM, Nida M, Aggarwal S, Sajid H, Naseem J, Loomba R (2013) Serum inflammatory markers in obstructive sleep apnea: a meta-analysis. J Clin Sleep Med 9(10):1003\u20131012","journal-title":"J Clin Sleep Med"},{"key":"1920_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1475-2840-8-61","volume":"8","author":"CN Rathcke","year":"2009","unstructured":"Rathcke CN, Vestergaard H (2009) YKL-40- an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 8:61","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1920_CR9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/jim-2017-000680","volume":"66","author":"NR El Basha","year":"2018","unstructured":"El Basha NR, Osman HM, Abdelaal AA, Saed SM, Shaaban HH (2018) Increased expression of serum periostin and YKL40 in children with severe asthma and asthma exacerbation. J Investig Med 66(8):1102\u20131108","journal-title":"J Investig Med"},{"issue":"8","key":"1920_CR10","doi-asserted-by":"crossref","first-page":"e0183294","DOI":"10.1371\/journal.pone.0183294","volume":"12","author":"T V\u00e4\u00e4n\u00e4nen","year":"2017","unstructured":"V\u00e4\u00e4n\u00e4nen T, Vuolteenaho K, Kautiainen H, Nieminen R, M\u00f6tt\u00f6nen T, Hannonen P, Korpela M, Kauppi MJ, Laiho K, Kaipiainen-Sepp\u00e4nen O, Luosuj\u00e4rvi R, Uusitalo T, Uutela T, Leirisalo-Repo M, Moilanen E, NEO-RACo Study Group (2017) Glycoprotein YKL-40: a potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS One 12(8):e0183294","journal-title":"PLoS One"},{"issue":"2","key":"1920_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2337\/dc08-1144","volume":"32","author":"CN Rathcke","year":"2009","unstructured":"Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H (2009) YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 32(2):323\u2013328","journal-title":"Diabetes Care"},{"key":"1920_CR12","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1111\/j.1440-1746.2007.05121.x","volume":"23","author":"Y Erzin","year":"2008","unstructured":"Erzin Y, Uzun H, Karatas A, Celik AF (2008) Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn\u2019s disease. J Gastroenterol Hepatol 23:e357\u2013e362","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"1920_CR13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cardfail.2010.05.029","volume":"16","author":"O Bilim","year":"2010","unstructured":"Bilim O, Takeishi Y, Kitahara T, Ishino M, Sasaki T, Suzuki S, Shishido T, Kubota I (2010) Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure. J Card Fail 16(11):873\u2013879","journal-title":"J Card Fail"},{"issue":"5","key":"1920_CR14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336\u2013341","journal-title":"Int J Surg"},{"key":"1920_CR15","unstructured":"Borenstein M, Hedges L, Rothstein H (2007) Meta-analysis: fixed effect vs. random effects. Available from: \nMeta-analysis.com\n\n. Accessed June 17, 2017"},{"issue":"18","key":"1920_CR16","first-page":"4161","volume":"21","author":"LC Mutlu","year":"2017","unstructured":"Mutlu LC, T\u00fcl\u00fcba\u015f F, Alp R, Kaplan G, Yildiz ZD, G\u00fcrel A (2017) Serum YKL-40 level is correlated with apnea hypopnea index in patients with obstructive sleep apnea sindrome. Eur Rev Med Pharmacol Sci 21(18):4161\u20134166","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1920_CR17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.sleep.2016.08.001","volume":"25","author":"B Jafari","year":"2016","unstructured":"Jafari B, Mohsenin V (2016) Chitinase-3-like protein-1 (YKL-40) as a marker of endothelial dysfunction in obstructive sleep apnea. Sleep Med 25:87\u201392","journal-title":"Sleep Med"},{"issue":"4","key":"1920_CR18","first-page":"333","volume":"43","author":"EM Bak\u0131rc\u0131","year":"2015","unstructured":"Bak\u0131rc\u0131 EM, \u00dcnver E, De\u011firmenci H, K\u0131van\u00e7 T, G\u00fcnay M, Hamur H, B\u00fcy\u00fckl\u00fc M, Ceyhun G, Topal E, \u00c7oban TA (2015) Serum YKL-40\/chitinase 3-like protein 1 level is an independent predictor of atherosclerosis development in patients with obstructive sleep apnea syndrome. Turk Kardiyol Dern Ars 43(4):333\u2013339","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"6","key":"1920_CR19","first-page":"857","volume":"16","author":"YP Hang","year":"2011","unstructured":"Hang YP, Xiao YL, Zhang DP, Cai HR (2011) Changes of serum levels of YKL-40 in patients with obstructive sleep apnea hypopnea syndrome and its clinical significance. Journal of Clinical Pulmonary Medicine 16(6):857\u2013858","journal-title":"Journal of Clinical Pulmonary Medicine"},{"key":"1920_CR20","first-page":"5193597","volume":"13","author":"K Li","year":"2019","unstructured":"Li K, Chen Z, Qin Y, Wei YX (2019) Plasm YKL-40 levels are associated with hypertension in patients with obstructive sleep apnea. Biomed Res Int 13:5193597","journal-title":"Biomed Res Int"},{"issue":"7","key":"1920_CR21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1164\/rccm.201105-0915OC","volume":"185","author":"I Bara","year":"2012","unstructured":"Bara I, Ozier A, Girodet PO, Carvalho G, Cattiaux J, Begueret H, Thumerel M, Ousova O, Kolbeck R, Coyle AJ, Woods J, Tunon de Lara JM, Marthan R, Berger P (2012) Role of YKL-40 in bronchial smooth muscle remodeling in asthma. Am J Respir Crit Care Med 185(7):715\u2013722","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"1920_CR22","doi-asserted-by":"crossref","first-page":"15332","DOI":"10.1074\/jbc.M110.212514","volume":"286","author":"RA Francescone","year":"2011","unstructured":"Francescone RA, Scully S, Falbish M, Taylor SL, Oh D, Moral L, Yan W, Bentley B, Shao R (2011) Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 286(17):15332\u201315343","journal-title":"J Biol Chem"},{"issue":"3","key":"1920_CR23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1309\/LMS98AKCXRSL2XOR","volume":"45","author":"W Li","year":"2014","unstructured":"Li W, Yu Z, Jiang C (2014) Association of serum YKL-40 with the presence and severity of obstructive sleep apnea syndrome. Lab Med 45(3):220\u2013225","journal-title":"Lab Med"},{"issue":"3","key":"1920_CR24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5578\/tt.9753","volume":"63","author":"S Duru","year":"2015","unstructured":"Duru S, Y\u00fcce G, F\u0131rat H, \u015eim\u015fek B, U\u00e7ar F, Ard\u0131\u00e7 S, Kurt EB (2015) YKL-40: may be use as a new inflammatory biomarker in obstructive sleep apnea syndrome? Tuberk Toraks 63(3):158\u2013164","journal-title":"Tuberk Toraks"},{"issue":"1","key":"1920_CR25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/00365513.2013.859726","volume":"74","author":"X Wang","year":"2014","unstructured":"Wang X, Xing GH (2014) Serum YKL-40 concentrations are elevated and correlated with disease severity in patients with obstructive sleep apnea syndrome. Scand J Clin Lab Invest 74(1):74\u201378","journal-title":"Scand J Clin Lab Invest"},{"key":"1920_CR26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1620\/tjem.229.163","volume":"229","author":"A Gumus","year":"2013","unstructured":"Gumus A, Kayhan S, Cinarka H, Kirbas A, Bulmus N, Yavuz A, Sahin U, Ozkaya S (2013) High serum YKL-40 level in patients with COPD is related to hypoxemia and disease severity. Tohoku J Exp Med 229:163\u2013170","journal-title":"Tohoku J Exp Med"},{"issue":"5","key":"1920_CR27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/pcad.1999.0410367","volume":"41","author":"JW Weiss","year":"1999","unstructured":"Weiss JW, Launois SH, Anand A, Garpestad E (1999) Cardiovascular morbidity in obstructive sleep apnea. Prog Cardiovasc Dis 41(5):367\u2013376","journal-title":"Prog Cardiovasc Dis"},{"issue":"7","key":"1920_CR28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.imbio.2012.10.015","volume":"218","author":"M Harutyunyan","year":"2013","unstructured":"Harutyunyan M, Gotze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kj\u00f8ller E, Kolmos HJ, Gluud C, Kastrup J (2013) Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology 218(7):945\u2013951","journal-title":"Immunobiology"},{"issue":"9","key":"1920_CR29","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/eurheartj\/ehp049","volume":"30","author":"J Kastrup","year":"2009","unstructured":"Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kj\u00f8ller E, Kolmos HJ, Lind I, Nielsen H, Gluud C, CLARICOR Trial Group (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30(9):1066\u20131072","journal-title":"Eur Heart J"},{"issue":"6","key":"1920_CR30","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.imbio.2011.11.003","volume":"217","author":"M Harutyunyan","year":"2012","unstructured":"Harutyunyan M, Christiansen M, Johansen JS, Kober L, Torp-Petersen C, Kastrup J (2012) The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 217(6):652\u2013656","journal-title":"Immunobiology"},{"issue":"5","key":"1920_CR31","volume":"9","author":"B Jafari","year":"2014","unstructured":"Jafari B, Elias JA, Mohsenin V (2014) Increased plasma YKL-40\/chitinase-3-like-protein-1 is associated with endothelial dysfunction in obstructive sleep apnea. PLoS One 9(5):e98629","journal-title":"PLoS One"},{"issue":"5","key":"1920_CR32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.chest.2017.05.009","volume":"152","author":"S Reutrakul","year":"2017","unstructured":"Reutrakul S, Mokhlesi B (2017) Obstructive sleep apnea and diabetes: a state of the art review. Chest 152(5):1070\u20131086","journal-title":"Chest"},{"issue":"3","key":"1920_CR33","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.4238\/2015.August.3.15","volume":"14","author":"L Sun","year":"2015","unstructured":"Sun L, Liu JY, Li LR (2015) Serum YKL-40 levels are associated with type 2 diabetes mellitus in patients with obstructive sleep apnea syndrome. Genet Mol Res 14(3):8919\u20138925","journal-title":"Genet Mol Res"},{"issue":"2","key":"1920_CR34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00011-005-0010-8","volume":"55","author":"CN Rathcke","year":"2006","unstructured":"Rathcke CN, Johansen JS, Vestergaard H (2006) YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 55(2):53\u201359","journal-title":"Inflamm Res"},{"issue":"4","key":"1920_CR35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11325-018-1731-6","volume":"22","author":"UD Teitsdottir","year":"2018","unstructured":"Teitsdottir UD, Arnardottir ES, Bjornsdottir E, Gislason T, Petersen PH (2018) Obesity modulates the association between sleep apnea treatment and CHI3L1 levels but not CHIT1 activity in moderate to severe OSA: an observational study. Sleep Breath 22(4):1101\u20131109","journal-title":"Sleep Breath"}],"container-title":["Sleep and Breathing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-019-01920-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11325-019-01920-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-019-01920-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T11:24:33Z","timestamp":1597317873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11325-019-01920-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1920"],"URL":"https:\/\/doi.org\/10.1007\/s11325-019-01920-5","relation":{},"ISSN":["1520-9512","1522-1709"],"issn-type":[{"type":"print","value":"1520-9512"},{"type":"electronic","value":"1522-1709"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"assertion":[{"value":"19 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}